Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: Outcome of an expert roundtable

British Journal of Ophthalmology

Volumn 96, Issue 1, 2012, Pages 3-9

  Cursiefen, Claus ^a   Colin, Joseph ^b   Dana, Reza ^c   Diaz Llopis, Manuel ^d,e,f   Faraj, Lana A ^g   Garcia Delpech, Salvador ^d,e,f   Geerling, Gerd ^h   Price, Francis W ⁱ   Remeijer, Lies ^j   Rouse, Barry T ^k   Seitz, Berthold ^l   Udaondo, Patricia ^d,f   Meller, Daniel ^m   Dua, Harminder ^g  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HÔPITAL PELLEGRIN   (France)

^c SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

^f CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^g UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^h UNIVERSITY OF WÜRZBURG   (Germany)

ⁱ Lautert)   (United States)

^j ROTTERDAM EYE HOSPITAL   (Netherlands)

^k UNIVERSITY OF TENNESSEE   (United States)

^l SAARLAND UNIVERSITY   (Germany)

^m UNIVERSITY OF DUISBURG ESSEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; BEVACIZUMAB; CHEMICAL COMPOUND; CORTICOSTEROID; PEGAPTANIB; RANIBIZUMAB; STEROID;

AMOEBIC KERATITIS; ANTIANGIOGENIC THERAPY; BACTERIAL KERATITIS; CHEMICAL BURN; CORNEA DISEASE; CORNEA NEOVASCULARIZATION; CORNEA SURGERY; DEEP LAMELLAR ENDOTHELIAL KERATOPLASTY; DEGENERATIVE DISEASE; DESCEMET MEMBRANE ENDOTHELIAL KERATOPLASTY; DESCEMET STRIPPING ENDOTHELIAL KERATOPLASTY; DISEASE ASSOCIATION; DRUG INDICATION; EYE DISEASE; EYE TUMOR; FINE NEEDLE DIATHERMY; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS; HUMAN; HYPOXIA; INFECTIOUS KERATITIS; INFLAMMATION; KERATITIS; KERATOMYCOSIS; LASER SURGERY; LIMBAL STEM CELL DEFICIENCY; LIMBAL STEM CELL TRANSPLANTATION; PENETRATING KERATOPLASTY; PREVALENCE; PRIORITY JOURNAL; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS KERATITIS;

ANGIOGENESIS INHIBITORS; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; HUMANS; OPHTHALMOLOGY; PRACTICE GUIDELINES AS TOPIC;

EID: 84455168698     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2011.204701     Document Type: Review

References (84)

1. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006;104:264-302.
2. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-9. (Pubitemid 32751680)
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998;43:245-69. (Pubitemid 28558273)
4. Whitsett CF, Stulting RD. The distribution of HLA antigens on human corneal tissue. Invest Ophthalmol Vis Sci 1984;25:519-24. (Pubitemid 14149142)
5. Al-Ghamdi A, Al-Rajhi A, Wagoner MD. Primary pediatric keratoplasty: indications, graft survival, and visual outcome. J AAPOS 2007;11:41-7. (Pubitemid 46329468)
6. Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010;117:1300-5.
7. Huang PT. Penetrating keratoplasty in infants and children. J AAPOS 2007;11:5-6. (Pubitemid 46329474)
8. Panda A, Vanathi M, Kumar A, et al. Corneal graft rejection. Surv Ophthalmol 2007;52:375-96. (Pubitemid 46901076)
9. Sellami D, Abid S, Bouaouaja G, et al. Epidemiology and risk factors for corneal graft rejection. Transplant Proc 2007;39:2609-11. (Pubitemid 47588385)
10. Albuquerque RJ, Hayashi T, Cho WG, et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009;15:1023-30.
11. Ambati BK, Nozaki M, Singh N, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006;443:993-7. (Pubitemid 44646176)
12. Cursiefen C, Chen L, Saint-Geniez M, et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006;103:11405-10. (Pubitemid 44156530)
13. Dana M, Streilein J. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996;37:2485-94. (Pubitemid 26391286)
14. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998;17:611-13. (Pubitemid 28511907)
15. Conn H, Berman M, Kenyon K, et al. Stromal vascularization prevents corneal ulceration. Invest Ophthalmol Vis Sci 1980;19:362-70. (Pubitemid 11081143)
16. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization. Pathogenesis and inhibition. Cornea 1987;6:250-7. (Pubitemid 18005952)
17. Hayashi K, Hooper L, Detrick B, et al. HSV immune complex (HSV-IgG: IC) and HSV-DNA elicit the production of angiogenic factor VEGF and MMP-9. Archives of Virology 2009;154:219-26.
18. Madigan MC, Penfold PL, Holden BA, et al. Ultrastructural features of contact lens-induced deep corneal neovascularization and associated stromal leukocytes. Cornea 1990;9:144-51. (Pubitemid 20153856)
19. Wong AL, Weissman BA, Mondino BJ. Bilateral corneal neovascularization and opacification associated with unmonitored contact lens wear. Am J Ophthalmol 2003;136:957-8. (Pubitemid 37330060)
20. Kokotas H, Petersen MB. Clinical and molecular aspects of aniridia. Clin Genet 2010;77:409-20.
21. Dua HS, Azuara-Blanco A. Limbal stem cells of the corneal epithelium. Surv Ophthalmol 2000;44:415-25. (Pubitemid 30151147)
22. Mochimaru H, Usui T, Yaguchi T, et al. Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest Ophthalmol Vis Sci 2008;49:2172-7.
23. Applegate LA, Ley RD. DNA damage is involved in the induction of opacification and neovascularization of the cornea by ultraviolet radiation. Exp Eye Res 1991;52:493-7.
24. Cogan DG. Corneal vascularization. Invest Ophthalmol Vis Sci 1962;1:253-61.
25. Said DG, Mathew M, Shaikh MY, et al. Diffuse keratoconjunctival proliferation: a novel clinical manifestation. Arch Ophthalmol 2008;126:1226-32.
26. Cursiefen C, Chen L, Dana MR, et al. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003;22:273-81. (Pubitemid 36359171)
27. Banerjee K, Biswas PS, Kim B, et al. CXCR2-/- mice show enhanced susceptibility to herpetic stromal keratitis: a role for IL-6-induced neovascularization. J Immunol 2004;172:1237-45. (Pubitemid 38113787)
28. Zheng M, Deshpande S, Lee S, et al. Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis. J Virol 2001;75:9828-35. (Pubitemid 32900118)
29. Sharma S, Mulik S, Kumar N, et al. An anti-inflammatory role of VEGFR2/Src kinase inhibitor in HSV-1 induced immunopathology. J Virol 2011;85:5995-6007.
30. Yuan X, Wilhelmus KR. Corneal neovascularization during experimental fungal keratitis. Mol Vis 2009;15:1988-96.
31. Barker KS, Park H, Phan QT, et al. Transcriptome profile of the vascular endothelial cell response to Candida albicans. J Infect Dis 2008;198:193-202. (Pubitemid 352019284)
32. Hurt M, Apte S, Leher H, et al. Exacerbation of Acanthamoeba keratitis in animals treated with anti-macrophage inflammatory protein 2 or antineutrophil antibodies. Infect Immun 2001;69:2988-95. (Pubitemid 32332192)
33. Fong GH. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med 2009;87:549-60.
34. Makino Y, Cao R, Svensson K, et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001;414:550-4. (Pubitemid 33131538)
35. Cursiefen C, Kuchle M, Naumann GO. Changing indications for penetrating keratoplasty: histopathology of 1,250 corneal buttons. Cornea 1998;17:468-70. (Pubitemid 28420676)
36. Hos D, Bachmann B, Bock F, et al. Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Exp Eye Res 2008;87:427-32.
37. Vajpayee RB, Sharma N, Sinha R, et al. Infectious keratitis following keratoplasty. Surv Ophthalmol 2007;52:1-12. (Pubitemid 46038355)
38. Yamagami S, Hamrah P, Miyamoto K, et al. CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium. Invest Ophthalmol Vis Sci 2005;46:1201-7. (Pubitemid 41685854)
39. Kuchle M, Cursiefen C, Nguyen NX, et al. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch Clin Exp Ophthalmol 2002;240:580-4. (Pubitemid 36097090)
40. Lim P, Fuchsluger TA, Jurkunas UV. Limbal stem cell deficiency and corneal neovascularization. Semin Ophthalmol 2009;24:139-48.
41. Uy HS, Chan PS, Ang RE. Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008;27:70-3.
42. Cursiefen C, Wenkel H, Martus P, et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Graefes Arch Clin Exp Ophthalmol 2001;239:514-21. (Pubitemid 32725422)
43. Pillai CT, Dua HS, Hossain P. Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000;41:2148-53. (Pubitemid 30450986)
44. Baer JC, Foster CS. Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology 1992;99:173-9.
45. Cherry PM, Faulkner JD, Shaver RP, et al. Argon laser treatment of corneal neovascularization. Ann Ophthalmol 1973;5:911-20.
46. Cherry PM, Garner A. Corneal neovascularization treated with argon laser. Br J Ophthalmol 1976;60:464-72.
47. L'Esperance FA Jr. Clinical photocoagulation with the organic dye laser. A preliminary communication. Arch Ophthalmol 1985;103:1312-16.
48. L'Esperance FA Jr, Mittl RN, James WA Jr. Carbon dioxide laser trabeculostomy for the treatment of neovascular glaucoma. Ophthalmology 1983;90:821-9. (Pubitemid 13036759)
49. Marsh RJ. Lasering of lipid keratopathy. Trans Ophthalmol Soc U K 1982;102:154-6. (Pubitemid 13248678)
50. Marsh RJ, Marshall J. Treatment of lipid keratopathy with the argon laser. Br J Ophthalmol 1982;66:127-35. (Pubitemid 12166864)
51. Reed JW, Fromer C, Klintworth GK. Induced corneal vascularization remission with argon laser therapy. Arch Ophthalmol 1975;93:1017-19.
52. Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-9.
53. Cursiefen C, Bock F, Horn FK, et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009;116:1630-7.
54. Remeijer L, Duan R, van Dun JM, et al. Prevalence and clinical consequences of herpes simplex virus type 1 DNA in human cornea tissues. J Infect Dis 2009;200:11-19.
55. Schreiber W, Olbrisch A, Vorwerk CK, et al. Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. Invest Ophthalmol Vis Sci 2003;44:2634-43. (Pubitemid 36618424)
56. Abshire R, Cockrum P, Crider J, et al. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther 2004;26:191-6. (Pubitemid 38339011)
57. Kremer I, Cohen EJ, Eagle RC Jr, et al. Histopathologic evaluation of stromal inflammation in Acanthamoeba keratitis. CLAO J 1994;20:45-8. (Pubitemid 24037852)
58. Dart JK, Saw VP, Kilvington S. Acanthamoeba keratitis: diagnosis and treatment update 2009. Am J Ophthalmol 2009;148:487-99. e2.
59. Dua HS, Azuara-Blanco A. Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Indian J Ophthalmol 1999;47:3-9.
60. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994;101:1536-47. (Pubitemid 24347052)
61. Williams KA. The Australian Corneal Graft Registry: 2004 Report. 2004. http://www.flinders.edu.au/medicine/sites/ophthalmology/clinical/ the-australian-corneal-graft-registry.cfm
62. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008;126:71-7.
63. Birnbaum F, Reis A, Reinhard T. [Immune suppression following perforating keratoplasty]. Ophthalmologe 2007;104:371-2.
64. Remeijer L, Osterhaus A, Verjans G. Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm 2004;12:255-85. (Pubitemid 40138184)
65. Sehrawat S, Suryawanshi A, Hirashima M, et al. Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators. J Immunol 2009;182:3191-201.
66. Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 2004;165:2177-85. (Pubitemid 39578394)
67. Zheng M, Schwarz MA, Lee S, et al. Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 2001;159:1021-9. (Pubitemid 32847192)
68. Hill JC. Systemic cyclosporine in high-risk keratoplasty: long-term results. Eye (Lond) 1995;9:422-8.
69. Bachmann BO, Luetjen-Drecoll E, Bock F, et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 2009;93:1075-80.
70. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 2004;45:2666-73. (Pubitemid 38998863)
71. Dietrich T, Bock F, Yuen D, et al. Cutting edge: Lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010;184:535-9.
72. Cursiefen C, Kruse FE. [DMEK: Descemet membrane endothelial keratoplasty]. Ophthalmologe 2010;107:370-6.
73. Price MO, Giebel AW, Fairchild KM, et al. Descemet's membrane endothelial keratoplasty: prospective multicenter study of visual and refractive outcomes and endothelial survival. Ophthalmology 2009;116:2361-8.
74. McCauley MB, Price FW Jr, Price MO. Descemet membrane automated endothelial keratoplasty: hybrid technique combining DSAEK stability with DMEK visual results. J Cataract Refract Surg 2009;35:1659-64.
75. Cauchi PA, Ang GS, Azuara-Blanco A, et al. A systematic literature review of surgical interventions for limbal stem cell deficiency in humans. Am J Ophthalmol 2008;146:251-9.
76. Shortt AJ, Secker GA, Notara MD, et al. Transplantation of ex vivo cultured limbal epithelial stem cells: a review of techniques and clinical results. Surv Ophthalmol 2007;52:483-502. (Pubitemid 47268554)
77. Rama P, Bonini S, Lambiase A, et al. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. Transplantation 2001;72:1478-85. (Pubitemid 33095504)
78. Shortt AJ, Secker GA, Rajan MS, et al. Ex vivo expansion and transplantation of limbal epithelial stem cells. Ophthalmology 2008;115:1989-97.
79. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-82.
80. Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010;363:147-55.
81. Ang LP, Tanioka H, Kawasaki S, et al. Cultivated human conjunctival epithelial transplantation for total limbal stem cell deficiency. Invest Ophthalmol Vis Sci 2010;51:758-64.
82. Joussen AM, Poulaki V, Mitsiades N, et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 2003;44:117-23. (Pubitemid 36134263)
83. Leippi S, Grehn F, Geerling G. [Antiangiogenic therapy for pterygium recurrence]. Ophthalmologe 2009;106:413-19.
84. Bock F, Onderka J, Hos D, et al. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 2008;87:462-70.